Bio-Techne Corporation
TECHHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. The company carries a $11.36B market cap, placing it firmly in the large-cap category. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Market Cap
$11.36B
Beta
1.27
P/E (TTM)
62.44
P/E (Fwd)
31.40
EPS (TTM)
$1.16
EPS (Fwd)
$2.31
ROE
9.0%
ROA
6.7%
Cash
$265.5M
Total Debt
$289.1M
Free CF
$229.7M
52W Change
33.6%
Annual Financials
Cash vs Debt
Where TECH stands vs its 150-day and 200-day moving averages
As of the August 17, 2026 close, TECH finished 21.01% above its 150-day moving average ($59.83) and 20.69% above its 200-day moving average ($59.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TECH overbought or oversold?
At the August 17, 2026 close, TECH's RSI(14) was 71.7, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bio-Techne Corporation carries $289.1M in total debt against $265.5M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $229.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 9.0%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $1.14B (2023) to $1.22B (2026).
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Bio-Techne Corporation's trajectory.